Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prolgolimab - Biocad

Next Previous
Drug Profile

Prolgolimab - Biocad

Alternative Names: Anti PD-1 mAb; Anti-PD-1 monoclonal antibody; BCD-100 - Biocad; Forteca

Latest Information Update: 05 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocad
  • Developer Biocad; N. N. Blokhin Cancer Research Center; Pavlov First State Medical University of Saint Petersburg; SPH-BIOCAD
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Malignant melanoma
  • Phase III Cervical cancer; Non-small cell lung cancer
  • Phase II Colorectal cancer; Hodgkin's disease
  • No development reported Solid tumours

Most Recent Events

  • 07 Sep 2024 Efficacy, pharmacokinetics and adverse event data from the phase III DOMAJOR trial in Non-small cell lung cancer presented at the 25th World Conference on Lung Cancer (WCLC-2024)
  • 02 Jun 2023 Interim safety and efficacy data from a phase II CAESURA trial presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 10 Mar 2023 Phase-II clinical trials in Hodgkin's disease (Combination therapy, In adults, In the elderly, Second-line therapy or greater) in Russia (IV) (NCT05757466)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top